|Bid||4.62 x 1200|
|Ask||5.38 x 800|
|Day's Range||5.23 - 5.33|
|52 Week Range||4.35 - 6.45|
|Beta (3Y Monthly)||1.23|
|PE Ratio (TTM)||21.79|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.33|
In an effort to stave off Amazon, CVS will roll-out nationwide delivery of prescription medication. Yahoo Finance's Seana Smith, Ethan Wolff-Mann, David Pogue and Rick Newman discuss.
Engineers in both the energy and biotech sectors are among top earners, surpassing Wall Street. Yahoo Finance's Seana Smith, Jennifer Rogers and Pras Subramanian discuss.
Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today preliminary and unaudited total revenues for the fourth quarter and full-year 2018. Total revenue for the fourth quarter of 2018 is expected to be between $46.7 million and $48.7 million. Total revenue for full-year 2018 is expected to be between $113 million and $115 million. Kamada’s initial full-year 2018 total revenue guidance of $116 million to $120 million was previously revised to $102 million to $108 million as a result of the now settled labor strike at the Company’s Beit Kama production facility in Israel.
Kamada (KMDA) delivered earnings and revenue surprises of -350.00% and -42.37%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Rehovot, Israel-based company said it had a loss of 6 cents per share. Losses, adjusted for stock option expense, came to 5 cents per share. The biopharmaceutical posted revenue of $15 million in the ...
Total Revenues for First Nine Months of 2018 were $66.3 Million, a 1% Decrease Year-Over-YearGross Profit for First Nine Months of 2018 was $20.2 million, a 1% Decrease.
REHOVOT, Israel, Nov. 05, 2018 -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results.
Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today the appointment of Eitan Kyiet as Vice President of Business Development. Mr. Kyiet has over 20 years of experience in business development, strategic operations and corporate law, with a significant portion of his career spent in the life sciences industry. Mr. Kyiet will report directly to Amir London, Kamada’s Chief Executive Officer.
Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, Board of Directors is proud to announce its addition of Dr Giloz-Ran, former manager of Grants Capital Investment, at INTEL Corporation, Israel - to its advisory board. "We are honored to have Dr. Giloz-Ran join our Board of Advisors, her exceptional record in international business management suits us well as our state-of-the-art laboratory comes into operation and we are being approached by potential medical partners to explore joint ventures," said Eyal Ballan, CTO.
The Zacks Analyst Blog Highlights: American River, BG Staffing, Evolution Petroleum, Kamada and Farmers & Merchants
Lira loses more than 20% over the week as international markets react to the uncertainty over Turkey's capability to repay foreign-currency debts. Dollar hits a one-year high.
Kamada (KMDA) delivered earnings and revenue surprises of 55.56% and 14.20%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Rehovot, Israel-based company said it had profit of 14 cents. The biopharmaceutical posted revenue of $33.8 million in the period. Kamada shares have climbed 22 percent since ...
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Kamada Ltd (NASDAQ: KMDA ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 8:30:00 AM Eastern Time. To listen ...
The U.S. medical device industry has exhibited strong and sustainable growth of late due to an aging population and increasing incidences of chronic and lifestyle diseases. Elimination of the tax will result in huge savings for the medical device players, in turn compelling them to focus on innovation. Per consulting specialist Emergo, the U.S. medical device industry was valued at $147.7 billion in 2016 and is projected to grow significantly through 2019 to $173 billion.